England is taking a bold step to tackle the deadly impact of bowel cancer, the UK's second-biggest cancer killer. But here's the catch: the NHS is stirring up controversy by adjusting the sensitivity of a crucial test, aiming to save lives but potentially causing a stir among experts.
The faecal immunochemical test (Fit), a powerful tool for detecting bowel cancer by identifying blood in stool samples, is getting an upgrade. NHS England is lowering the blood detection threshold, meaning even smaller amounts of blood will trigger further investigation. This change is expected to increase the number of people sent for colonoscopies, a diagnostic procedure for bowel cancer.
Currently, the threshold is set at 120 micrograms of blood per gram of stool. But by 2028, it will be reduced to 80 micrograms, aligning England with Scotland and Wales. NHS leaders believe this move will enhance early detection and save hundreds of lives from this devastating disease.
But here's where it gets controversial: Some argue that lowering the threshold may lead to overdiagnosis and unnecessary procedures. However, NHS England's national clinical director for cancer, Prof Peter Johnson, emphasizes the benefits: "Testing at a lower threshold will improve early detection, allowing us to treat cancers sooner and potentially before symptoms appear."
Bowel cancer is a significant health concern, with approximately 44,100 new cases and 17,400 deaths annually in Britain. Lifestyle factors like processed meat consumption, obesity, and alcohol intake contribute to over half of these cases.
The NHS estimates that this new approach will reduce late-stage diagnoses and deaths by around 6%, potentially saving the health service £32 million annually. Moreover, it is anticipated to lead to the detection of 600 additional bowel cancers each year, an 11% increase compared to the current test.
The Fit test, introduced in 2019 as part of the NHS's home screening program, has been a game-changer. Eligible individuals receive the test by post, providing a stool sample for laboratory analysis. In 2023-2024, the NHS sent kits to nearly 7 million people, with a 68% return rate, identifying 5,320 cancers. The age criteria have recently expanded, now including those aged 50-53, adding 1.2 million more people to the screening pool.
Bowel Cancer UK's CEO, Genevieve Edwards, praised the lower threshold as a significant advancement for England's bowel cancer screening. However, a recent charity report highlights a concerning trend: 25% of bowel cancers are only diagnosed when patients end up in emergency care due to severe symptoms.
And this is the part most people miss: While the NHS's move is a step forward, it also raises questions about the balance between early detection and potential overdiagnosis. How can we ensure that increased sensitivity doesn't lead to unnecessary anxiety and procedures? This is a delicate tightrope the NHS must navigate, and it invites discussion on the best approach to cancer screening and treatment.
